Discovery of LY3325656: a GPR142 agonist suitable for clinical testing in human
2019
Abstract The discovery and optimization of a novel series of GPR142 agonists are described. These led to the identification of compound 21 (LY3325656), which demonstrated anti-diabetic benefits in pre-clinical studies and ADME/PK properties suitable for human dosing. Compound 21 is the first GPR142 agonist molecule advancing to phase 1 clinic trials for the treatment of Type 2 diabetes. 2019 Elsevier Ltd. All rights reserved
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
15
References
3
Citations
NaN
KQI